Review: Targeted Therapies in Systemic Lupus Erythematosus
New research shows even more potential for targeted therapies in systemic lupus erythematosus, a disease that is often characterized as a combination several systemic autoimmune diseases.
Increased Risk of Leukemia Associated with an Autoimmune Disease Treatment
Researchers reporting at the American Society of Hematology annual meeting this week say there is a link between a treatment for autoimmune disease and the development of leukemia.
A Lupus Medication Decision Aid Made Simple
Doctor and patients perceive the importance of lupus medications differently. In this article, we feature a UAB-derived decision aid that highlights key considerations.
Achieving Low Disease Activity in SLE
Less than half of patients with systemic lupus erythematosus reach low disease activity. Why? Experts say focus on disease duration, phenotype and other accepted predictive factors.
Case Study: Chikungunya and Lupus, an Ill-Fated Diagnosis
Diagnosed with systemic lupus erythematosus and chikungunya, a woman embarks on a cross-continent trip for treatment and diagnosis at a city hospital.
38% Higher Risk of Stroke in SLE
Patients with systemic lupus erythematosus have a 38 percent higher adjusted risk of stroke, shows a Harvard study presented at ACR 2016.
Rituximab and Other Therapies for SLE
A report in Joint Bone Spine conveys which biotherapies offer the most potential for systemic lupus erythematosus.
By clicking Accept, you agree to become a member of the UBM Medica Community.